Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Levomilnacipran hydrochloride
Drug ID BADD_D01280
Description Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor. Chemically, levomilnacipran is the 1S,2R-enantiomer of milnacipran. FDA approved on July 25, 2013.
Indications and Usage Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
Marketing Status approved; investigational
ATC Code N06AX28
DrugBank ID DB08918
KEGG ID D10133
MeSH ID D000078862
PubChem ID 6917778
TTD Drug ID D02XOK
NDC Product Code 50370-0043; 0456-2221; 53069-1090; 0456-2202; 0456-2212; 0456-2220; 0456-2200; 0456-2281; 69766-018; 0456-2280; 0456-2213; 0456-2241; 53069-1100; 51604-1183; 0456-2240
UNII 371U2ZK31U
Synonyms Levomilnacipran | Fetzima | Levomilnacipran Hydrochloride
Chemical Information
Molecular Formula C15H23ClN2O
CAS Registry Number 101152-94-7
SMILES CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Heart rate increased13.14.04.002---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypomania19.16.02.001---
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Liver function test abnormal13.03.04.030---
Loss of consciousness17.02.04.004---
Mania19.16.02.002--
Menopausal symptoms21.02.02.002---
Migraine17.14.02.001; 24.03.05.003---
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Orthostatic hypotension17.05.01.020; 24.06.03.004---
Palpitations02.11.04.012--
Panic attack19.06.04.001---
Paraesthesia17.02.06.005; 23.03.03.094--
Pollakiuria20.02.02.007--
Premature ejaculation19.08.01.002; 21.03.01.008---
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Rash23.03.13.001---
Rash erythematous23.03.13.029---
Rash macular23.03.13.003---
Rash maculo-papular23.03.13.004--
Seizure17.12.03.001--
Seminal vesiculitis21.09.01.004---
Serotonin syndrome12.03.01.041; 15.05.04.016; 17.05.02.004---
Shock24.06.02.002---
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages